描述 |
Diclofenac potassium 是一种有效的,非选择性抗炎剂,为 COX 的抑制剂,在 CHO 细胞中,对人 COX-1 和 COX-2 的 IC50 值分别为 4 和 1.3 nM。Diclofenac potassium 对绵羊 COX-1 和 COX-2 的 IC50 值分别为 5.1 μM,0.84 μM。Diclofenac potassium 通过活化 caspase 级联反应来诱导神经干细胞凋亡 (apoptosis)。 |
||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
相关类别 |
|
||||||||||||
靶点 |
Human COX-2:1.3 nM (IC50, in CHO cells)
Human COX-1:4 nM (IC50, in CHO cells)
Ovine COX-2:0.84 nM (IC50)
Ovine COX-1:5.1 nM (IC50)
|
||||||||||||
体外研究 |
双氯芬酸能有效地阻断COX-1介导的U937细胞微粒体产生前列腺素,IC50为7±3nm[1]。双氯芬酸(1-60μM;1天)以浓度依赖的方式诱导神经干细胞(NSCs)死亡[3]。双氯芬酸(10-60μM;6小时)增加裂解(激活)caspase-3的表达[3]。细胞活力测定[3]细胞系:神经干细胞(NSCs)浓度:1、3、10、30、60μM孵育时间:1天结果:诱导细胞死亡呈浓度依赖性,在高达60μM的浓度下效果不饱和。Western Blot分析[3]细胞系:神经干细胞(NSCs)浓度:10,30或60μM孵育时间:6h结果:caspase-3活性呈浓度依赖性增加。 |
||||||||||||
体内研究 |
双氯芬酸(3 mg/kg,b.i.d.,5天)显著增加大鼠粪便中51Cr的排泄,在每天两次给药1 mg/kg,连续4天后,在松鼠猴中也观察到这种作用[1]。双氯芬酸(10 mg/kg;在炎症诱导前经口给药)在Wistar大鼠体内显示抗炎活性[1]。动物模型:雄性Sprague-Dawley大鼠(150±200 g)[1]剂量:3 mg/kg给药:口服,b.i.d.,连续5天结果:导致粪便51Cr排泄量显著增加。动物模型:Wistar大鼠(150-175 g),福尔马林诱导大鼠足爪水肿模型[2]剂量:10 mg/kg给药:炎症诱导前经口给药结果:显示体内抗炎活性(水肿抑制率=29.2,1 h;22.2,3 h;20,6 h)。 |
||||||||||||
存储 |
|
||||||||||||
运输 |
室温 |
||||||||||||
SMILES |
O=C(O[K])CC1=CC=CC=C1NC2=C(Cl)C=CC=C2Cl |
||||||||||||
参考文献 |
|
沸点 | 412?C at 760 mmHg |
---|---|
熔点 | 156-158?C |
分子式 | C14H10Cl2KNO2 |
分子量 | 334.239 |
闪点 | 203?C |
精确质量 | 332.972565 |
PSA | 52.16000 |
LogP | 3.10240 |
外观性状 | 白色至淡黄色结晶粉末 |
蒸汽压 | 1.59E-07mmHg at 25°C |
符号 |
GHS07, GHS09 |
---|---|
信号词 |
Warning |
危害声明 |
H302-H411 |
警示性声明 |
P301 + P312 + P330 |
危害码 (欧洲) |
T: Toxic; |
风险声明 (欧洲) |
22-51/53 |
安全声明 (欧洲) |
61 |
危险品运输编码 | UN 2811 6.1 / PGIII |
海关编码 | 2922499990 |
海关编码 | 2922499990 |
---|---|
中文概述 | 2922499990 其他氨基酸及其酯及它们的盐(含有一种以上含氧基的除外). 增值税率:17.0% 退税率:9.0% 监管条件:AB(入境货物通关单,出境货物通关单) 最惠国关税:6.5% 普通关税:30.0% |
申报要素 | 品名, 成分含量, 用途, 乙醇胺及其盐应报明色度, 乙醇胺及其盐应报明包装 |
监管条件 | A.入境货物通关单 B.出境货物通关单 |
检验检疫 | P.进境动植物、动植物产品检疫 Q.出境动植物、动植物产品检疫 R.进口食品卫生监督检验 S.出口食品卫生监督检验 M.进口商品检验 N.出口商品检验 |
Summary | HS:2922499990 other amino-acids, other than those containing more than one kind of oxygen function, and their esters; salts thereof VAT:17.0% Tax rebate rate:9.0% Supervision conditions:AB(certificate of inspection for goods inward,certificate of inspection for goods outward) MFN tariff:6.5% General tariff:30.0% |
The advantages and limitations of the analgesics available for control of postoperative pain after a dental procedure. SAAD Dig. 29 , 70-81, (2013)
|
|
Chitosan/glucose 1-phosphate as new stable in situ forming depot system for controlled drug delivery. Eur. J. Pharm. Biopharm. 88(2) , 361-73, (2014)
Chitosan (CS)-based thermosensitive solutions that turn into semi-solid hydrogels upon injection at body temperature have increasingly drawn attention over the last decades as an attractive new type o…
|
|
Cystoid macular edema from cancer-associated retinopathy. Optom. Vis. Sci. 91(4 Suppl 1) , S66-70, (2014)
This article reviews the diagnosis and management of a patient with cancer-associated retinopathy (CAR) secondary to small cell lung cancer who developed a rare presentation of CAR, cystoid macular ed…
|
|
Diclofenic potassium |
Potassium {2-[(2,6-dichlorophenyl)amino]phenyl}acetate |
Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-, potassium salt (1:1) |
potassium 2-(2-(2,6-dichlorophenylamino)phenyl)acetate |
2-((2,6-Dichlorophenyl)amino)benzeneacetic Acid Monopotassium Salt |
Diclofenac potassium |
2-{2-[(2,6-dichlorophenyl)amino]phenyl}acetic acid, potassium salt |
Potassium [2-[(2,6-dichlorophenyl)amino]phenyl]acetate |
UNII-L4D5UA6CB4 |
MFCD00082254 |
Cataflam |
CGP 45840B |
CGP-45840B |
2-[(2,6-Dichlorophenyl)amino]benzeneacetic acid potassium salt, Diclofenac potassium salt |